Related Experiment Videos
Isaacs' syndrome successfully treated by immunoadsorption plasmapheresis.
Y Nakatsuji1, M Kaido, F Sugai
1Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan. yuji@neurol.med.osaka-u.ac.jp
Acta Neurologica Scandinavica
|November 9, 2000
Summary
Immunoadsorption plasmapheresis (IAP) significantly improved Isaacs' syndrome symptoms in a long-term patient. While symptoms recurred, IAP offered sustained relief, suggesting its therapeutic potential for this rare autoimmune disorder.
Area of Science:
- Neurology
- Immunology
- Medical Technology
Background:
- Isaacs' syndrome, also known as acquired neuromyotonia, is a rare autoimmune disorder characterized by peripheral nerve hyperexcitability.
- The condition can manifest with symptoms such as hyperhidrosis and progressive neuromyotonia, significantly impacting quality of life.
- Long-term management of Isaacs' syndrome remains challenging, necessitating exploration of novel therapeutic strategies.
Observation:
- A 70-year-old woman with a 50-year history of Isaacs' syndrome presented with persistent neuromyotonia and hyperhidrosis.
- In vitro studies indicated the presence of antibodies targeting potassium channels in the patient's serum.
- The patient had a history of hyperhidrosis since her teens.
Findings:
- Immunoadsorption plasmapheresis (IAP) led to a complete disappearance of the patient's neuromyotonia symptoms.
- Serum antibody analysis using patch-clamp techniques suggested autoimmune targeting of potassium channels.
- Following IAP, symptom recurrence was observed within three weeks.
Implications:
- IAP demonstrates significant therapeutic potential for managing severe cases of Isaacs' syndrome.
- The findings support the hypothesis of an autoimmune etiology involving potassium channel antibodies in acquired neuromyotonia.
- Combination therapy with IAP and subsequent immunosuppressive drugs may offer sustained symptom control for patients with Isaacs' syndrome.